Low polydispersity, low molecular weight biotechnological chondroitin sulfate with anti-inflammatory and antiarthritis activity and use thereof in the prevention of osteoarthritis
US10632144B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 27, 2018 |
| Grant date | Apr 28, 2020 |
| Priority date | — |
| Expiry date | Sep 27, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a low molecular weight (1000-5000 daltons) chondroitin sulfate (CS) produced by chemical sulfation of a non-sulfated chondroitin backbone (K4 capsular polysaccharide) obtained with biotechnology techniques. The CS described is substantially monosulfated, mainly at the 6-position, with very little sulfation at the 4-position, and with a mono/disulfated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin sulfate (CS) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.